Cooley has 900 lawyers across 12 offices in the United States, China and Europe. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. We have a fully integrated IP litigation, counseling and prosecution practice and are called on to litigate IP disputes involving core technologies, products and brands. Visit us as: www.cooley.com.
Barclay Damon LLP, listed as a “Top 250 Firm” by The National Law Journal, is a full-service, 275-attorney law firm with offices throughout the major cities of Albany, Boston, Buffalo, Newark, New York City, Syracuse, Toronto, and Washington, D.C. Barclay Damon provides comprehensive legal and business counsel to a diverse client base in 33 practice areas, including pharmaceutical and life sciences counseling and litigation as well as healthcare law. Barclay Damon’s IP attorneys are regularly called upon to counsel pharmaceutical and biotechnology manufacturers regarding intellectual property matters including freedom-to-operate analyses, due diligence investigations, infringement/validity/enforceability analyses, enforcement, regulatory (FDA) issues, and licensing negotiations, as well as Hatch-Waxman and medical device litigation.
Jason Lief is a patent litigator who focuses on pharmaceutical and Hatch-Waxman litigation. For more than two decades Jason has represented some of the world’s most renowned innovators in dozens of cases often involving billion-dollar products, establishing a winning track record and a reputation for courtroom excellence. Jason has litigated and tried dozens of Hatch-Waxman and other pharmaceutical patent cases before federal courts throughout the US, including cases involving Zantac®; Wellbutrin®; Wellbutrin SR®; Wellbutrin XL®; Ceftin®; Intuniv®; Vyvanse®; Oxtellar XR®; Angiomax® and Lialda®. In addition, Jason has litigated biotech, chemical and consumer products patent cases, as well as copyright, trademark and trade secret cases. He has argued before the US Court of Appeals for the Federal Circuit and also made appearances in foreign courts pursuant to the Hague Convention.
Bella S. Satra is a senior associate in the Intellectual Property Litigation and Commercial Litigation Practice Areas at Barclay Damon LLP. Bella focuses her practice in patent and complex commercial litigation and has represented clients in various areas and industries, including pharmaceuticals, medical devices, broadband and telecommunications, and electric power generation, transmission and distribution systems. Prior to joining Barclay Damon, she practiced at a large international law firm in San Francisco, handling matters that involved intellectual property, antitrust and unfair competition, bankruptcy, and contract disputes. Bella is also experienced in appellate litigation and has briefed or argued matters before the Second Circuit, Ninth Circuit, Federal Circuit and the New York Appellate Division.